A US company that has incorporated dark adaptometry into a new wearable headset for age-related macular degeneration (AMD) is on...
Read moreIn a historical development for the eye health sector, the Therapeutics Goods Administration (TGA) has approved the country’s first true...
Read moreA biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial...
Read moreMelbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met...
Read moreA biopharmaceutical company that is developing cheaper anti-VEGF treatments for major global markets, including Australia, has reported positive results from...
Read moreMacular Disease Foundation Australia (MDFA) has launched a series of community service announcements featuring national icon Ms Ita Buttrose in...
Read moreA safety review into Novartis’ new anti-VEGF drug Beovu has revealed that reported adverse events are consistent with the approved...
Read moreResults are imminent in biopharmaceutical company Opthea’s latest clinical trial evaluating the safety and efficacy of its lead drug candidate...
Read moreNovartis is working to ensure its newly-approved drug Beovu is accessible via the Pharmaceutical Benefits Scheme (PBS) at the earliest...
Read moreA new approach that uses an algorithm to analyse retinal images could help practitioners select the best treatment for patients...
Read moreInsight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited